HEOR

• HTA DOSSIER DEVELOPMENT OR ADAPTATION: HTA (Health Technology Assessment) dossiers are comprehensive documents that evaluate the clinical, economic, and social impact of a health technology (such as a drug, medical device, or diagnostic test). These dossiers provide evidence to inform decision-makers about the technology’s value and potential benefits for the national budgets. In Ukraine and other CEE/Baltic countries, HTA dossiers should be tailored to local healthcare systems, epidemiological data, and patient needs. Adaptation involves customizing existing dossiers to fit regional requirements, language, and relevant clinical practices.
• COST-BENEFIT ANALYSIS (CBA): CBA assesses the economic feasibility of a project or intervention by comparing its projected benefits to the associated costs. It helps decision-makers determine whether an investment is worthwhile. When evaluating healthcare interventions in Ukraine and neighboring countries, CBA considers local cost structures, currency exchange rates, and societal preferences. It quantifies both direct medical costs (e.g., treatments, diagnostics) and indirect costs (e.g., lost productivity).
• COST OF DISEASE/ DISEASE BURDEN ANALYSIS: This analysis estimates the economic impact of a specific disease or condition. It includes direct medical costs, productivity losses, and intangible costs (such as pain and suffering). For Ukraine and CEE/Baltic countries, understanding disease burden is crucial. Consider factors like prevalence, treatment costs, hospitalization rates, and the impact on patients, families, and society.
• BUDGET IMPACT ANALYSIS (BIA): estimates the economic impact of a specific medical intervention, considering direct medical costs, productivity losses, and intangible costs (such as pain and suffering). For market access in the CEE, Ukraine, and the Baltic States, BIA is crucial because it informs resource allocation decisions, ensures efficient use of healthcare funds, and helps evaluate the financial implications of adopting new pharmaceutical and medtech products.
• SYSTEMATIC REVIEWS: This service is about synthesizing existing evidence from multiple studies to answer specific research questions. They follow rigorous methods to minimize bias and provide a comprehensive overview. In Ukraine and neighboring regions, systematic reviews help inform clinical guidelines, policy decisions, and resource allocation. Consider local studies, language barriers, and cultural nuances when conducting or using systematic reviews, especially when reviewing evidence available on the local language only.
• META-ANALYSIS OF EFFICACY AND SAFETY of medicines/medical devices: Meta-analyses combine data from multiple randomized controlled trials (RCTs) to assess the effectiveness and safety of medicines or medical devices. They provide more robust evidence than individual studies. In Ukraine and CEE/Baltic countries, meta-analyses should consider regional variations in patient populations, healthcare infrastructure, and regulatory standards. Transparency in methodology and prespecification of analyses are essential.
• Other ad-hoc HTA-related studies: These studies cover various aspects related to health technology assessment, such as budget impact analyses, patient-reported outcomes, and real-world evidence. Customized ad-hoc studies can address specific local needs. Collaborate with local experts, policymakers, and stakeholders to ensure relevance and practicality.

Remember that successful implementation of these services relies on collaboration, accurate data, and alignment with the unique context of Ukraine CEE, and the Baltic States.